Millichap John J, Koh Sookyong, Laux Linda C, Nordli Douglas R
Division of Neurology, Children's Memorial Hospital, Northwestern University Medical School, Chicago, IL 60614, USA.
Neurology. 2009 Sep 29;73(13):e59-62. doi: 10.1212/WNL.0b013e3181b9c880.
Dravet syndrome (DS), previously known as severe myoclonic epilepsy in infancy (SMEI), is an epileptic encephalopathy that presents with prolonged seizures in the first year of life. The seizures often occur with fever or illness, and are frequently initially categorized as febrile seizures. The correct diagnosis of DS and appropriate follow-up are typically delayed. The EEG is normal at onset, and neuroimaging reveals no structural lesion. Early development is normal, but signs of regression appear in the second year of life and are often accompanied by convulsive status epilepticus, alternating hemiconvulsions, and myoclonic seizures. Diagnosis can be confirmed by genetic testing that is now available, and shows mutations within the SCN1A gene. Early recognition and diagnosis of DS and management with appropriate anticonvulsants and treatment plan may reduce the seizure burden and improve long-term developmental outcome.
德拉韦综合征(DS),以前称为婴儿严重肌阵挛性癫痫(SMEI),是一种癫痫性脑病,在生命的第一年出现长时间发作。发作常伴有发热或疾病,最初常被归类为热性惊厥。DS的正确诊断和适当随访通常会延迟。发病时脑电图正常,神经影像学检查未发现结构性病变。早期发育正常,但在生命的第二年出现倒退迹象,常伴有惊厥性癫痫持续状态、交替性偏瘫惊厥和肌阵挛发作。现在可通过基因检测确诊,检测显示SCN1A基因存在突变。DS的早期识别和诊断以及采用适当的抗惊厥药物和治疗方案进行管理,可能会减轻发作负担并改善长期发育结果。